Suppr超能文献

钙拮抗剂在动脉硬化进展中的作用。来自动物实验和临床经验的证据。第二部分。钙通道阻滞剂对动脉粥样硬化性冠状动脉疾病预防作用的临床经验。

Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part II. Clinical experience with preventive effects of calcium channel blockers in atheromatous coronary artery disease.

作者信息

Just H, Frey M

机构信息

Medizinische Universitätsklinik, Abt. Innere Medizin III, Kardiologie und Angiologie, Freiburg, FRG.

出版信息

Basic Res Cardiol. 1994;89 Suppl 1:177-84.

PMID:7945172
Abstract

Experimental evidence for antiatheromatous of effects of calcium antagonists has been impressive. Clinical experience has, in contrast, been more difficult to obtain. Primary prevention with calcium antagonists has not been studied due to obvious difficulties. Secondary prevention, however, has been investigated: Several studies have addressed influence of calcium antagonists upon atheromatous arterial wall changes as demonstrated by quantitative coronary angiocardiography. A review of these studies reveals considerable methodological problems. For nifedipine it could be demonstrated, however, that the occurrence of "new lesions" can be retarded to a certain extent (3-6). Nicardipine has been studied, but the preventive effect reported cannot be considered valid, because distribution of risk factors to the study groups was not statistically homogeneous. Another approach has been the application of calcium antagonists to patients with acute myocardial infarction. Here, vascular and myocardial effects come into play. In non-Q-wave, i.e. not transmural infarction, the calcium antagonist diltiazem definitely has preventive effects as regards re-infarction (2). The large multicenter post-myocardial infarction trial MDPIT showed an improvement of cardiac envent rate and re-infarction. This effect was seen only if pulmonary congestion was not present. Calcium antagonists have negative effects if cardiac failure is present. Verapamil was shown to have beneficial effects in acute myocardial infarction in the large DAVIT trials. Here again, the effect was only seen if heart failure was not present. Otherwise negative results were recorded. Nifedipine demonstrated only borderline myocardial protective effects in acute myocardial infarction (7). We conclude that calcium antagonists have vascular and myocardial protective effects.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

钙拮抗剂抗动脉粥样硬化作用的实验证据令人印象深刻。相比之下,临床经验却更难获得。由于存在明显困难,尚未对钙拮抗剂的一级预防作用进行研究。然而,已经对二级预防进行了调查:多项研究探讨了钙拮抗剂对动脉粥样硬化性动脉壁变化的影响,这种影响通过定量冠状动脉造影得以证实。对这些研究的综述揭示了相当多的方法学问题。不过,对于硝苯地平,可以证明“新病变”的发生在一定程度上能够得到延缓(3 - 6)。尼卡地平也有相关研究,但所报道的预防效果不能被认为有效,因为研究组中危险因素的分布在统计学上并不均匀。另一种方法是将钙拮抗剂应用于急性心肌梗死患者。在此情况下,血管和心肌效应开始发挥作用。在非Q波型,即非透壁性梗死中,钙拮抗剂地尔硫䓬对于再梗死肯定具有预防作用(2)。大型多中心心肌梗死后试验MDPIT显示心脏事件发生率和再梗死情况有所改善。仅在不存在肺充血的情况下才会出现这种效果。如果存在心力衰竭,钙拮抗剂会产生负面影响。在大型DAVIT试验中,维拉帕米在急性心肌梗死中显示出有益效果。同样,仅在不存在心力衰竭的情况下才会出现这种效果。否则会记录到负面结果。硝苯地平在急性心肌梗死中仅显示出临界的心肌保护作用(7)。我们得出结论,钙拮抗剂具有血管和心肌保护作用。(摘要截选至250词)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验